Leflunomide Orion (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, which is essential for de novo pyrimidine synthesis. This limits the availability of nucleotides needed for rapid lymphocyte proliferation, especially activated T‑cells, and consequently dampens the autoimmune inflammatory response that drives joint damage.

The appropriate dose of Leflunomide Orion is individualized by the prescribing clinician based on the patient’s disease severity, prior therapy, liver function, and overall health status. Dosage decisions follow local prescribing guidelines and are not disclosed in public product literature.

Leflunomide is contraindicated in pregnancy because of known teratogenic risk, and women of child‑bearing potential must use effective contraception before, during, and for a defined period after treatment. Safety during breastfeeding has not been established, so the drug is generally avoided.

To place an order, submit an enquiry on the Leflunomide Orion product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with methotrexate, another first‑line DMARD, leflunomide offers a once‑daily oral regimen and may be preferred when methotrexate is poorly tolerated or ineffective. Both drugs share hepatic monitoring requirements, but leflunomide has a longer half‑life and a distinct safety profile that includes a higher risk of pulmonary toxicity.

Leflunomide Orion tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Leflunomide Orion is taken orally as a whole tablet with a glass of water. It is usually swallowed whole and not chewed or crushed. The exact timing and any loading dose are determined by the prescribing physician based on individual therapeutic goals.

The most critical risks include severe liver injury, bone‑marrow suppression leading to anemia or low white‑blood‑cell counts, interstitial lung disease or pneumonitis, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Prompt reporting of symptoms like jaundice, persistent fever, respiratory difficulty or rash is essential.

Leflunomide Orion should be avoided in patients who are pregnant, planning pregnancy, or not using reliable contraception. It is also contraindicated in individuals with severe hepatic impairment, active infections, uncontrolled hypertension, or known hypersensitivity to leflunomide or related compounds.